Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27732
Title: Botox rechallenge-An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation.
Austin Authors: Timm, Brennan ;Jayarajan, Jyotsna ;Chan, Garson ;Bolton, Damien M 
Affiliation: Urology
North Eastern Urology, Heidelberg, Victoria, Australia
Issue Date: Jan-2021
metadata.dc.date: 2020-06-16
Publication information: Lower Urinary Tract Symptoms 2021; 13(1): 194-197
Abstract: Two female patients aged 70 and 72 with video-urodynamics-confirmed detrusor overactivity and detrusor underactivity (DO-DU) were treated. Patients were refractory to medical therapies and had previously failed intravesical botulinum toxin type A (BoNT-A) at other centers secondary to urinary retention and difficulty with self-catheterization. Placement of an Interstim II device (Medtronic, Minneapolis, Minnesota) for sacral neuromodulation (SNM) as alternative third-line treatment partially improved overactive bladder (OAB) symptoms while significantly improving voiding symptoms. Postvoid residual (PVR) of patients improved from a median of 118 mL (110-125 mL) to 20 mL (18-26 mL) and 213 mL (195-230 mL) to 70 mL (60-73 mL), respectively. Addition of medical therapies post SNM failed to modify OAB symptoms further and a rechallenge with dose-reduced BoNT-A was undertaken.OAB symptoms were significantly improved by addition of BoNT-A, while urinary retention was avoided (median PVR post BoNT-A 38 mL [34-40 mL] and 185 mL [150-205 mL], respectively). Reduction in incontinence pad use as well as resolution of nighttime incontinence in both patients and daytime incontinence in one patient was achieved. DO-DU patients treated by SNM who have improved bladder emptying (PVR <100 mL) but incomplete resolution of OAB symptoms should be trialed on adjunct medical therapies to improve OAB symptoms. If OAB symptoms are still inadequately controlled, consideration of a rechallenge with BoNT-A, particularly with dose reduction, appears to be efficacious and avoids symptomatic retention in this challenging cohort.
URI: https://ahro.austin.org.au/austinjspui/handle/1/27732
DOI: 10.1111/luts.12332
ORCID: 0000-0001-6195-3364
0000-0002-2241-6635
PubMed URL: 32548938
Type: Journal Article
Subjects: BoNT-A
Botox
DO-DU
OAB
UUI
acute urinary retention
overactive bladder
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.